An array of new tools, perspectives, and guidelines to help navigate the gray areas have been reported in recent days.
Wanted: Physicians who will interact with patients the way a good financial counselor would.
A range of options for metastatic castration resistant prostate cancer offer benefits, but impact on survival and sequencing guidance are less than optimal.
Risk does not go up with exposure to testosterone therapy over a 5-year period or according to total testosterone injections.
The goal is to avoid treating men who don’t need surgery or radiation. A new long-term study points to the potential of surveillance as a treatment option.
Lethal prostate cancer is less—not more—likely to develop in patients with asthma. The Health Professionals Follow-up Study answers key questions about why.
Three factors may help physicians identify older men who are unlikely to benefit from aggressive therapy, and other prostate cancer news.
A video series from James Mohler of Rosweel Park Cancer Institute on PSA testing in the wake of changing guidelines from the US Preventive Task Force.
James Mohler, MD, Roswell Park Cancer Institue, discusses risk factors for prostate cancer.
James Mohler, MD, Roswell Park Cancer Institute, defines who is at risk for prostate cancer, how to decide who should be screened, and how to talk to patients about the test and their results.